
==== Front
Biomed Rep
Biomed Rep
BR
Biomedical Reports
2049-9434
2049-9442
D.A. Spandidos

BR-19-3-01643
10.3892/br.2023.1643
Articles
A case of acquired hemophilia A after pancreaticoduodenectomy for distal cholangiocarcinoma
Takahashi Makoto 1
Morita Yasuhiro 1
Hayashi Tatsuya 1
Higashihara Taku 1
Kawasaki Keishi 1
Sato Shunsuke 1
Yokose Shota 1
Sasaki Shu 1
Funakoshi Kaoruko 1
Sasaki Takayoshi 1
Zhou Daren 1
Ichinose Akinori 1
Ohtsuka Hideo 1
Ishibasi Yuji 1
Hatao Fumihiko 1
Shimizu Keiki 2
Isono Nobuo 3
Sasaki Naomi 4
Kozai Yasuji 5
Okada Haruka 6
Chikasawa Yushi 7
1 Department of Surgery, Tokyo Metropolitan Tama Medical Center, Tokyo 183-8524, Japan
2 Department of Critical Care and Emergency Medicine, Tokyo Metropolitan Tama Medical Center, Tokyo 183-8524, Japan
3 Department of Plastic Surgery, Tokyo Metropolitan Tama Medical Center, Tokyo 183-8524, Japan
4 Department of Nursing, Tokyo Metropolitan Tama Medical Center, Tokyo 183-8524, Japan
5 Department of Hematology, Tokyo Metropolitan Tama Medical Center, Tokyo 183-8524, Japan
6 Department of Pathology, Tokyo Metropolitan Tama Medical Center, Tokyo 183-8524, Japan
7 Department of Laboratory Medicine, Tokyo Medical University, Tokyo 183-8524, Japan
Correspondence to: Dr Makoto Takahashi, Department of Surgery, Tokyo Metropolitan Tama Medical Center, 2-8-29 Musashidai Fuchu-shi, Tokyo 183-8524, Japan guqing@zjcc.org.cn makoto_6_c@yahoo.co.jp
Abbreviations: AHA, acquired hemophilia A; APCC, activated prothrombin complex concentrate; APTT, activated partial thromboplastin time; CPA, cyclophosphamide; GFO, glutamine, fiber and oligosaccharide; ICU, intensive care unit; PD, postoperative day; PSL, prednisolone; PT, prothrombin time; SSPPD, subtotal stomach-preserving pancreaticoduodenectomy

9 2023
01 8 2023
01 8 2023
19 3 6116 5 2023
17 7 2023
Copyright: © Takahashi et al.
2020
https://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
Acquired hemophilia A (AHA) is a rare disease that results from factor VIII inhibitors causing abnormal coagulation, and certain cases may develop after highly invasive surgery. The present case study reports on a 68-year-old male patient who developed AHA after undergoing a subtotal stomach-preserving pancreatoduodenectomy for distal cholangiocarcinoma. The patient experienced complications after surgery, requiring reoperation on postoperative day (PD) 5 due to rupture of the Braun's enterostomy. On PD 6, angiography was performed after bleeding was detected in the jejunal limb, but hemostasis occurred spontaneously during the examination. Bleeding was observed again on PD 8 and direct surgical ligation was performed. On PD 14, bleeding recurred in the jejunal limb and angiography was performed to embolize the periphery of the second jejunal artery. During the procedure, the prothrombin time was normal, but only the activated partial thromboplastin time was prolonged. A close examination of the coagulation system revealed a decrease in factor VIII levels and the presence of factor VIII inhibitors, resulting in the diagnosis of AHA. Administration of steroids was initiated on PD 15 and, in addition to daily blood transfusions, activated prothrombin complex concentrate was administered to achieve hemostasis. The patient was discharged from the intensive care unit on PD 36 but later developed an intractable labial fistula due to suture failure at the gastrojejunostomy site. As the use of factor VIII inhibitors continued despite the administration of steroids, cyclophosphamide (CPA) pulse therapy was added at PD 58. However, CPA was ineffective and the administration of rituximab was initiated on PD 98. After 12 courses of rituximab, the patient tested negative for factor VIII inhibitors on PD 219. On PD 289, labial fistula closure was performed with continuous replacement of factor VIII and the patient was discharged on PD 342.

acquired hemophilia A
distal cholangiocarcinoma
subtotal stomach-preserving pancreaticoduodenectomy
surgery
activated prothrombin complex concentrate
factor VIII inhibitor
rituximab
recombinant factor VIII preparation
Funding: No funding was received.
==== Body
pmcIntroduction

Acquired hemophilia A (AHA) is a rare disease, that may result from factor VIII inhibitors causing abnormal coagulation. Patients with AHA are characterized by a prolonged activated partial thromboplastin time (APTT) despite a normal prothrombin time (PT) (1). In Japan, the incidence of AHA has been reported to be 0.8-1.83 per million individuals per year (2,3). Recently, the number of reported cases of AHA has increased (4). There is no gender difference in the incidence of AHA, but it tends to be more common in the elderly (5). AHA presents suddenly with subcutaneous or intramuscular hemorrhage in patients without a history or family history of bleeding tendencies (6). The bleeding phenotype of AHA is variable, ranging from life-threatening bleeds to mild or no bleeding (5). Patients with AHA also have a high early-onset mortality rate, most of which are caused by severe hemorrhage and severe infections (7). AHA has been reported to be associated with autoimmune diseases, malignant tumors, pregnancy, delivery and drugs (8-10). According to certain reports, AHA may develop after surgery (11,12). The present study reported a case of AHA that developed after subtotal stomach-preserving pancreaticoduodenectomy (SSPPD) for distal cholangiocarcinoma.

Case report

A 68-year-old male presented to the emergency department of Tokyo Metropolitan Tama Medical Center (Tokyo, Japan) with upper abdominal pain in September 2019. The patient was a sedentary worker on active duty and had no apparent history of carcinogen exposure. He had no history of dementia, hepatitis B or C, or diabetes. The patient was diagnosed with gallstone pancreatitis at the first visit and underwent endoscopic retrograde cholangiography the next day, during which a plastic stent was placed at the department of gastroenterology. However, endoscopic removal of a common bile duct stone revealed stenosis due to a neoplastic lesion in the distal bile duct, and a biopsy confirmed distal cholangiocarcinoma, so the patient was referred to our department in November 2019. Preoperative blood tests indicated that no blasts were present.

The patient underwent SSPPD as the first surgery. Intraoperative rapid diagnosis was performed according to standard procedures, and the result was positive for a bile duct stump, so additional resection was performed. The bile duct stump was negative for cancer, and had two holes: The posterior segment branch of the low confluence and the common hepatic duct (Fig. 1), which formed a hole for the hepatocholangiojejunostomy. The operative time was 608 min, the amount of bleeding was 1,055 ml and no blood transfusion was required.

Pathological examination was performed by standard procedures and revealed a well-to-moderately differentiated tubular adenocarcinoma (pT1, pN1, pM0, pStage IIA) (Fig. 2A and B). On postoperative day (PD) 3, the patient developed a surgical site infection, and on PD 5, intestinal juice leaked from the wound, requiring a second surgery to resuture the Braun's anastomotic rupture. On PD 6, there was significant bleeding from the gastric tube and dynamic computed tomography showed bleeding into the jejunal limb. Angiography was performed, but hemostasis occurred spontaneously during the examination (first angiography). On PD 8, bleeding in the jejunal limb reoccurred and direct surgical ligation was performed (third operation) (Fig. 3). There was a small hole in the Braun's enterostomy and gastrojejunostomy sutures. The afferent leg was transected, bypassing to the anal side, and the hole was closed on the efferent leg side. The gastrostomy tube was inserted through the suture failure of the gastrojejunostomy. On PD 14, bleeding recurred in the jejunal limb and angiography was performed to embolize the periphery of the second jejunal artery (second angiography) (Fig. 4).

As the patient continued to exhibit hemorrhagic tendencies, a prolonged activated partial thromboplastin time (APTT) (44.5 sec) was observed from PD 2, despite the preoperative APTT (22.9 sec) being within the almost normal range (24.3-36.0 sec). Although the prothrombin time (PT) was within the normal range postoperatively, the APTT reached 91.5 sec on PD 12. On PD 14, acquired hemophilia A (AHA) was suspected and activated prothrombin complex concentrate (APCC; FEIBA®; 100 U/kg, q12h, four times) was administered while performing a coagulation factor activity test. Prednisolone (PSL) was also started on PD 15 at 1 mg/kg/day. However, the gastrojejunostomy site was perforated, resulting in a labial fistula. On PD 18, the diagnosis of AHA was confirmed by a decrease in factor VIII activity (<1%; normal range, 60-150%), the appearance of a factor VIII inhibitor (18 BU/ml; normal value, undetectable) and the absence of a lupus anticoagulant. Other results of coagulation factor activity tests were as follows: Factor IX activity, 73% (normal range, 70-130%), factor IX inhibitor, 0 BU/ml (normal value, undetectable); factor XIII activity, 37% (normal range, 70-140%), von Willebrand factor, 294% (normal range, 60-170%); anticardiolipin antibody-anti-β2-glycoprotein I, <1.2 U/ml (upper limit of normal, 3.5 U/ml). Loss due to hemorrhage was thought to be the reason for the decreased factor XIII clotting activity.

On PD 21, blood transfusion was no longer required and hemostasis was observed, allowing us to initiate the administration of glutamine, fiber and oligosaccharide (GFO) through the intestinal fistula. However, on PD 22, the patient experienced melena and anemia progressed, prompting us to halt the administration of GFO and administer APCC for two days.

However, on PD 26, melena resumed and APCC was administered again for two days. The administration of GFO was resumed on PD 29 through an intestinal fistula, but it was required to stop again on PD 31 due to the recurrence of melena, leading to the administration of APCC for three days. The patient also exhibited decreased factor XIII activity, and hence, freeze-dried blood-coagulation factor XIII derived from human plasma (Fibrogammin P®; CSL Behring; 1,440 U/day) was administered for three days. By PD 36, the patient was stable and was discharged from the intensive care unit (ICU) (Fig. 5A), after receiving APCC for 10 days and 102 units of red blood cells. Hemostasis was achieved by PD 41 and enteral nutrition was resumed.

On PD 58, the factor VIII inhibitor levels increased (54 BU/ml), prompting the initiation of combination therapy with cyclophosphamide (CPA; 15 mg/kg, every three weeks) and PSL. On PD 79, negative pressure wound therapy was started at a different wound location from the labial fistula of the wound (Fig. 6A and B). On PD 98, the factor VIII inhibitor levels increased (35 BU/ml), prompting the initiation of combination therapy with rituximab (375 mg/m2, weekly) and PSL. With treatment, the factor VIII inhibitor levels gradually decreased, factor VIII coagulation activity increased and APTT prolongation improved. The PSL dose was subsequently reduced gradually.

After 12 courses of rituximab, the factor VIII inhibitors became negative on PD 219, but factor VIII activity remained low at 20-30% (Fig. 5B). The patient was temporarily discharged on PD 245, with a labial fistula and enteral nutrition management (Fig. 6C). Surgery under general anesthesia was planned to close the labial fistula and it was decided to perform the surgery while supplementing factor VIII. On PD 268, a pharmacokinetic test was conducted by intravenous injection of a recombinant factor VIII preparation (rFVIII) (ADVATE®). As a result, in vivo recovery, half-life time and clearance using rFVIII was 1.79 (IU/dl)/(IU/kg), 17.6 h and 2.5 ml/kg/h, respectively. Suzuki et al (13) analyzed 34 patients and determined that the in vivo recovery, half-life time and clearance using rFVIII was 1.42±0.36 (IU/dl)/(IU/kg), 12 h and 4.25±2.25 ml/kg/h, respectively.

On PD 289, the fourth surgery was performed, trimming and closing the perforated site of the gastrojejunostomy with an Albert-Lembert suture. Before the surgery, a bolus dose of 58 IU/kg rFVIII was administered, and during the surgery, rFVIII was continuously infused at 2.35 IU/kg/h. Factor VIII coagulation activity was monitored during and after surgery, and the rFVIII dose was gradually reduced while maintaining ≥100%. On the third day after the fourth surgery (PD 292), continuous intravenous infusion of rFVIII was discontinued.

The patient was able to resume oral intake on PD 322 and was discharged from the hospital on PD 342 (Fig. 6D). However, on PD 765, the patient passed away due to the recurrence of liver metastasis from distal cholangiocarcinoma.

Discussion

AHA is a rare bleeding disorder caused by neutralizing autoantibodies known as inhibitors of coagulation factor VIII. It is associated with underlying conditions such as pregnancy, delivery, autoimmune diseases, malignant diseases and drug reactions (5). Napolitano et al (14) conducted a study involving 105 patients with AHA with underlying malignant tumors, including 60 solid tumors and 45 hematological malignancies. Prostate (25.3%) and lung (15.8%) cancers had the highest frequency, followed by colon cancer (9.5%). Of the 105 cases, only two (1.9%) had distal bile duct cancer. It is worth noting that the patient of the present study and the two aforementioned patients had no coagulation abnormalities prior to pancreaticoduodenectomy and they developed AHA after tumor resection.

In certain cases, AHA may develop following major surgery, including pancreatoduodenectomy (11,12,15). APCC (16) and recombinant activated factor VII (NovoSeven®) (17) preparations are typically used in the acute phase of AHA for hemostasis (5). Clinical trial data have indicated that recombinant porcine factor VII is also effective in treating AHA (18).

In the case of the present study, the bleeding was finally stopped after repeated use of APCC. For the chronic phase of AHA, international recommendations from 2020(5) suggest first-line treatment with PSL alone for three to four weeks for patients with factor VIII ≥1 IU/dl and inhibitor titer ≤20 BU at baseline (19), while those with factor VIII <1 IU/dl or inhibitor titer >20 BU receive a combination of PSL with rituximab or a cytotoxic agent (CPA or mycophenolate mofetil) as first-line treatment (20). As a second-line treatment, rituximab or a cytotoxic agent that was not used during first-line treatment has been suggested (19).

In the present case, factor VIII activity was <1% and factor VIII inhibitor was 18 BU. As the present case was encountered before the 2020 guidelines were published, PSL was first administered, followed by combination therapy of CPA and PSL as the second-line treatment and a combination of rituximab and PSL as the third-line treatment (1,21).

In the case of the present study, factor VIII inhibitor disappeared after 31 weeks of treatment. Reports of surgery in patients with AHA are scarce. As in the second and third surgeries in the present case, emergency surgery has been reported in the presence of a bleeding tendency (22-24), and while a small number of studies reported that surgery was performed after confirming negative factor VIII inhibitor status, as in the fourth surgery in the present case. Ichikawa et al (25) reported that a patient with AHA was treated with rituximab and underwent surgery for sigmoid colon cancer after the disappearance of factor VIII inhibitors with no adverse events. Jena et al (26) performed a pancreatoduodenectomy on a patient with periampullary carcinoma and AHA after treating AHA.

Upon scheduling intestinal fistula closure, it was observed that while factor VIII inhibitor had resolved, factor VIII activity remained low. In such cases, it becomes challenging to assess both hemostatic and thrombotic tendencies while using bypass preparations due to the incomplete resolution of AHA. Kruse-Jarres et al (27) reported that rFVIII replacement therapy is also a treatment option when the factor VIII inhibitor level is <5 BU/ml. There have been certain reported cases where hemostatic management and surgery were performed while administering rFVIII (28-31), and in the present case, hemostatic management with rFVIII under adequate monitoring was chosen. As a result, there were no perioperative bleeding or thrombotic complications and AHA did not recur.

The pathogenesis of AHA remains to be fully elucidated. Although in the present study, it was considered to measure autoantibodies and complement, they were not examined because the effects of surgical invasion and early initiation of immunosuppressive therapy with steroids may make the interpretation of the results difficult. In addition to malignant tumors and autoimmune diseases that have been reported so far, there have been an increasing number of reports of onset triggered by infectious diseases, such as reports related to COVID-19 (32-34). Furthermore, Alzheimer's dementia, hepatitis B and diabetes may also be important risk factors for AHA (35). In the case of the present study, AHA developed just after surgery for a malignant tumor, so it was difficult to collect information that may be related to the pathogenesis, but at least there was no background of Alzheimer's dementia, hepatitis B or diabetes. Further cases need to be accumulated to study the pathogenesis and establish a suitable management strategy.

Acknowledgements

Not applicable.

Availability of data and materials

The datasets used and/or analyzed in the current study are available from the corresponding author upon reasonable request.

Authors' contributions

MT drafted the manuscript. YM contributed to the preoperative checks and diagnoses. MT, THa, YM and ZD performed the initial surgery. MT, THa and ZD performed the second surgery. YM and MT performed the third surgery. YM, NI and MT performed the fourth surgery. KS directed the management of perioperative care for the patient in the care unit. YK and YC supervised hemostatic therapy and immunotherapy for the patient. NI and NS managed the patient's labial fistulas. FH contributed to the nutritional management of the patient. YM followed up the patient. THi, KK, SSat, SY, SSas, KF, TS, AI, HOh and YI provided postoperative management for the patient. HOk made the pathological diagnosis. MT and YK checked and approved the authenticity of the raw data. All authors have read and approved the final version of the manuscript.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Written informed consent was obtained from the patient for the publication of this case report.

Competing interests

The authors declare that they have no competing interests.

Figure 1 Intraoperative image indicating that the bile duct had two holes: The posterior segment branch of the low confluence and the common hepatic duct. CHA, common hepatic artery; GDA, gastroduodenal artery; PV, portal vein; HBD, hepatic bile duct; B6, posterior inferior subsegmental branch of bile duct; B7, posterior superior subsegmental branch of bile duct.

Figure 2 (A) Specimen before additional resection of bile duct, which had two tumors, highlighted by yellow circles (26x18 and 17x14 mm in size, nodular-expanding type). (B) Hematoxylin-eosin stain (scale bar, 1 mm). Histopathologically, both were well-to-moderately differentiated tubular adenocarcinomas.

Figure 3 On postoperative day 8, bleeding reoccurred in the jejunal limb and direct surgical ligation was performed.

Figure 4 On postoperative day 14, bleeding (yellow arrows) recurred in the jejunal limb and an angiography was performed to embolize the periphery of the second jejunal artery.

Figure 5 (A) Course of treatment at the ICU. PT was consistently within the normal range before and after surgery, but the APTT began to prolong after surgery and reached 91.5 secs on PD 12. Acquired hemophilia A was suspected on PD 14 and APCC was administered. The administration of steroids started on PD 15. While at the ICU, APCC was administered for 10 days and a total of 102 units of red blood cells were administered. (B) The long-term therapeutic course is indicated. On PD 58, CPA was administered in addition to steroids, but since factor VIII inhibitors increased, administration of rituximab was started on PD 98. After 12 courses of rituximab, the factor VIII inhibitor finally became negative on PD 219. ICU, intensive care unit; PT, prothrombin time; APTT, activated partial thromboplastin time; APCC, activated prothrombin complex concentrate; CPA, cyclophosphamide; PD, postoperative day; PSL, prednisolone; OPE, operation; RBC, red blood cells; Angio, angiography.

Figure 6 (A) The ruptured gastrojejunostomy suture appeared as a labial fistula (PD 79). (B) Negative pressure wound therapy in a place other than the labial fistula of the wound (PD 79). (C) The incision improved, leaving only a labial fistula (PD 245). (D) The incision was completely closed (PD 342). PD, postoperative day.
==== Refs
References

1 Huth-Kühne A Baudo F Collins P Ingerslev J Kessler CM Lévesque H Castellano ME Shima M St-Louis J International recommendations on the diagnosis and treatment of patients with acquired hemophilia A Haematologica 94 566 575 2009 10.3324/haematol.2008.001743 19336751
2 Ogawa Y Yanagisawa K Uchiumi H Ishizaki T Mitsui T Gouda F Ieko M Ichinose A Nojima Y Handa H Clinical characteristics and outcomes of acquired hemophilia A: experience at a single center in Japan Int J Hematol 106 82 89 2017 10.1007/s12185-017-2210-8 28299631
3 Ogawa Y Amano K Matsuo-Tezuka Y Okada N Murakami Y Nakamura T Yamaguchi-Suita H Nogami K ORIHIME study: Real-world treatment patterns and clinical outcomes of 338 patients with acquired hemophilia A from a Japanese administrative database Int J Hematol 117 44 55 2023 10.1007/s12185-022-03467-w 36331704
4 Tiede A Werwitzke S Scharf RE Laboratory diagnosis of acquired hemophilia A: Limitations, consequences, and challenges Semin Thromb Hemost 40 803 811 2014 10.1055/s-0034-1390004 25299927
5 Tiede A Collins P Knoebl P Teitel J Kessler C Shima M Di Minno G d'Oiron R Salaj P Jiménez-Yuste V International recommendations on the diagnosis and treatment of acquired hemophilia A Haematologica 105 1791 1801 2020 10.3324/haematol.2019.230771 32381574
6 Delgado J Jimenez-Yuste V Hernandez-Navarro F Villar A Acquired haemophilia: Review and meta-analysis focused on therapy and prognostic factors Br J Haematol 121 21 35 2003 10.1046/j.1365-2141.2003.04162.x 12670328
7 Collins PW Hirsch S Baglin TP Dolan G Hanley J Makris M Keeling DM Liesner R Brown SA Hay CR UK Haemophilia Centre Doctors' Organisation Acquired hemophilia A in the United Kingdom: A 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors' Organisation Blood 109 1870 1877 2007 10.1182/blood-2006-06-029850 17047148
8 Bossi P Cabane J Ninet J Dhote R Hanslik T Chosidow O Jouan-Flahault C Horellou MH Leynadier F Liozon E Acquired hemophilia due to factor VIII inhibitors in 34 patients Am J Med 105 400 408 1998 10.1016/s0002-9343(98)00289-7 9831424
9 Morrison AE Ludlam CA Kessler C Use of porcine factor VIII in the treatment of patients with acquired hemophilia Blood 81 1513 1520 1993 8453098
10 Green D Lechner K A survey of 215 non-hemophilic patients with inhibitors to Factor VIII Thromb Haemost 45 200 203 1981 6792737
11 Miura T Ban D Koyama T Kudo A Ochiai T Irie T Nakamura N Tanaka S Arii S Severe postoperative hemorrhage caused by antibody-mediated coagulation factor deficiencies: Report of two cases Surg Today 44 976 981 2014 10.1007/s00595-013-0584-7 23695294
12 Mekenkamp LJ Beishuizen A Slomp J Legdeur MC Klaase JM Trof RJ Successful treatment of fulminant postoperative bleeding due to acquired haemophilia Neth J Med 73 182 186 2015 25968291
13 Suzuki N Hirakawa A Kishimoto M Kanematsu T Ogawa M Kiyoi H Matsushita T Retrospective analysis of in vivo recovery and clearance during continuous infusion of recombinant factor VIII products: A single-institution study Haemophilia 23 215 221 2017 10.1111/hae.13082 27704637
14 Napolitano M Siragusa S Mancuso S Kessler CM Acquired haemophilia in cancer: A systematic and critical literature review Haemophilia 24 43 56 2018 10.1111/hae.13355 28960809
15 Geethakumari PR Sama A Caro JG Yeo CJ Nagalla S ‘The Immune Conundrum’: Acquired Hemophilia A, immune thrombocytopenia, and neutropenia in a patient with pancreatic cancer Case Rep Pancreat Cancer 2 14 18 2016 10.1089/crpc.2015.29011.prg 30631809
16 Sallah S Treatment of acquired haemophilia with factor eight inhibitor bypassing activity Haemophilia 10 169 173 2004 10.1046/j.1365-2516.2003.00856.x 14962206
17 Tiede A Worster A Lessons from a systematic literature review of the effectiveness of recombinant factor VIIa in acquired haemophilia Ann Hematol 97 1889 1901 2018 10.1007/s00277-018-3372-z 29804265
18 Kruse-Jarres R St-Louis J Greist A Shapiro A Smith H Chowdary P Drebes A Gomperts E Bourgeois C Mo M Efficacy and safety of OBI-1, an antihaemophilic factor VIII (recombinant), porcine sequence, in subjects with acquired haemophilia A Haemophilia 21 162 170 2015 10.1111/hae.12627 25623166
19 Tiede A Klamroth R Scharf RE Trappe RU Holstein K Huth-Kühne A Gottstein S Geisen U Schenk J Scholz U Prognostic factors for remission of and survival in acquired hemophilia A (AHA): Results from the GTH-AH 01/2010 study Blood 125 1091 1097 2015 10.1182/blood-2014-07-587089 25525118
20 Collins P Baudo F Knoebl P Lévesque H Nemes L Pellegrini F Marco P Tengborn L Huth-Kühne A Immunosuppression for acquired hemophilia A: Results from the European Acquired Haemophilia Registry (EACH2) Blood 120 47 55 2012 10.1182/blood-2012-02-409185 22517903
21 Franchini M Acquired hemophilia A Hematology 11 119 125 2006 10.1080/10245330600574185 16753853
22 Gok E Akay MH de Armas IS Klein K Tint H Allison PM Chen AJ Akkanti B Kar B Gregoric ID Aortic root repair in a patient with acquired hemophilia A: case report Surg Case Rep 7 176 2021 10.1186/s40792-021-01256-x 34347197
23 Tjønnfjord GE Brinch L Gedde-Dahl T Brosstad FR Activated prothrombin complex concentrate (FEIBA) treatment during surgery in patients with inhibitors to FVIII/IX Haemophilia 10 174 178 2004 10.1046/j.1365-2516.2003.00857.x 14962207
24 Hay CR Negrier C Ludlam CA The treatment of bleeding in acquired haemophilia with recombinant factor VIIa: A multicentre study Thromb Haemost 78 1463 1467 1997 9423795
25 Ichikawa S Kohata K Okitsu Y Suzuki M Nakajima S Yamada MF Onishi Y Yamamoto J Suzuki S Ishizawa K Acquired hemophilia A with sigmoid colon cancer: Successful treatment with rituximab followed by sigmoidectomy Int J Hematol 90 33 36 2009 10.1007/s12185-009-0347-9 19484333
26 Jena SS Meher D Dhankar N Unforeseen encounter of acquired hemophilia A in a preoperative case of periampullary carcinoma: A case report Int J Surg Case Rep 79 146 149 2021 10.1016/j.ijscr.2021.01.038 33477072
27 Kruse-Jarres R Kempton CL Baudo F Collins PW Knoebl P Leissinger CA Tiede A Kessler CM Acquired hemophilia A: Updated review of evidence and treatment guidance Am J Hematol 92 695 705 2017 10.1002/ajh.24777 28470674
28 Shen M Wang S Sessa J Hanna A Axelrad A Ali F Acquired hemophilia A: A case report J Pharm Pract 33 562 566 2020 10.1177/0897190019826474 30727803
29 Prencipe MA D'Errico M Di Giorgio G Gatta G Gesuete A Nobile M Stallone C Macrohaematuria post-partum: An unusual case of acquired haemophilia after pregnancy G Ital Nefrol 19 204 208 2002 (In Italian) 12195420
30 Baudo F Collins P Huth-Kühne A Lévesque H Marco P Nemes L Pellegrini F Tengborn L Knoebl P EACH2 registry contributors Management of bleeding in acquired hemophilia A: results from the European Acquired Haemophilia (EACH2) Registry Blood 120 39 46 2012 10.1182/blood-2012-02-408930 22618709
31 Lindahl R Nummi V Lehtinen AE Szanto T Hiltunen L Olsson A Glenthoej A Chaireti R Vaide I Funding E Zetterberg E Acquired Haemophilia A in four north European countries: Survey of 181 patients Br J Haematol 201 326 333 2023 10.1111/bjh.18611 36541135
32 Guerra JD Gowarty J Buess J Mason J Halka K A case of acquired hemophilia a in a patient with exposure to COVID-19 Case Rep Hematol 2022 9494249 2022 10.1155/2022/9494249 35360457
33 Murali A Wong P Gilbar PJ Mangos HM Acquired Hemophilia A following Pfizer-BioNTech SARS CoV-2 mRNA vaccine, successfully treated with prednisolone and rituximab J Oncol Pharm Pract 28 1450 1453 2022 10.1177/10781552221075545 35088622
34 Franchini M Cappello E Valdiserra G Bonaso M Moretti U Focosi D Tuccori M Investigating a signal of acquired hemophilia associated with COVID-19 Vaccination: A systematic case review Semin Thromb Hemost 49 15 26 2023 10.1055/s-0042-1754389 36055265
35 Shoji-Asahina A Nakatani E Imaichi Y Ohata E Oshima M Miyakoshi A Miyake H Ichikawa Y Dote H Ubukata N Risk factors, treatment and survival rates of late-onset acquired haemophilia A: A cohort study from the Shizuoka Kokuho Database Haemophilia 29 799 808 2023 10.1111/hae.14793 37096498
